Alterity Therapeutics Limited Stock Performance
| PRNAF Stock | USD 0.01 0 71.43% |
Alterity Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Alterity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alterity Therapeutics is expected to be smaller as well. Use Alterity Therapeutics standard deviation, kurtosis, period momentum indicator, as well as the relationship between the jensen alpha and day median price , to analyze future returns on Alterity Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alterity Therapeutics Limited are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating basic indicators, Alterity Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 28.1 M | |
| Total Cashflows From Investing Activities | -89.1 K |
Alterity |
Alterity Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.70 in Alterity Therapeutics Limited on October 20, 2025 and sell it today you would earn a total of 0.38 from holding Alterity Therapeutics Limited or generate 54.29% return on investment over 90 days. Alterity Therapeutics Limited is currently producing 1.0061% returns and takes up 9.4134% volatility of returns over 90 trading days. Put another way, 84% of traded pink sheets are less volatile than Alterity, and 80% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Alterity Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alterity Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Alterity Therapeutics Limited, and traders can use it to determine the average amount a Alterity Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1069
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PRNAF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Alterity Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alterity Therapeutics by adding it to a well-diversified portfolio.
Alterity Therapeutics Fundamentals Growth
Alterity Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Alterity Therapeutics, and Alterity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alterity Pink Sheet performance.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 3.12 X | |||
| EBITDA | (15.08 M) | |||
| Cash And Equivalents | 34.81 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 117.49 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (12.34 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 41.36 M | |||
| Retained Earnings | (125 M) | |||
| Current Asset | 34 M | |||
| Current Liabilities | 2 M | |||
About Alterity Therapeutics Performance
By analyzing Alterity Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Alterity Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Alterity Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alterity Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Prana Biotechnology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 12 people.Things to note about Alterity Therapeutics performance evaluation
Checking the ongoing alerts about Alterity Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Alterity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alterity Therapeutics is way too risky over 90 days horizon | |
| Alterity Therapeutics has some characteristics of a very speculative penny stock | |
| Alterity Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (12.85 M) with profit before overhead, payroll, taxes, and interest of 4.76 M. | |
| Alterity Therapeutics Limited has accumulated about 34.81 M in cash with (12.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Alterity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alterity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Alterity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alterity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alterity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alterity Therapeutics' pink sheet. These opinions can provide insight into Alterity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Alterity Pink Sheet analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world |